BC
HALO icon

Bridgefront Capital’s Halozyme HALO Stock Holding History

Bridgefront Capital’s Portfolio HALO Stock Details HALO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-6,815
Closed -$500K – 631
2025
Q3 		$500K Buy
6,815
+295
+5% +$19.6K 0.15% 249
2025
Q2 		$339K Buy
+6,520
New +$371K 0.09% 393
2023
Q4 		– Sell
-6,238
Closed -$238K – 446
2023
Q3 		$238K Buy
+6,238
New +$256K 0.17% 274
2021
Q3 		– Sell
-9,230
Closed -$419K – 481
2021
Q2 		$419K Buy
9,230
+4,142
+81% +$183K 0.16% 230
2021
Q1 		$212K Sell
5,088
-6,916
-58% -$316K 0.07% 561
2020
Q4 		$513K Buy
+12,004
New +$431K 0.18% 201

Other funds holding HALO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SCM
Snyder Capital Management San Francisco, California $5.16B AUM 26.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Bridgefront Capital's HALO Position: Q4 2025 in Review

Bridgefront Capital sold out of Halozyme (HALO) in Q4 2025, closing a stake of 6,815 shares — an estimated $500K sold.

Bridgefront Capital first reported a position in HALO in Q4 2020 and held it in 6 quarters. The position peaked at $513K in Q4 2020. 617 funds tracked by Wall St. Rank hold HALO as of Q4 2025.

  • Bridgefront Capital reported no remaining Halozyme position as of Q4 2025 after selling out during the quarter.
  • Bridgefront Capital sold 6,815 Halozyme shares in Q4 2025, an estimated $500K.
  • Bridgefront Capital first reported a position in Halozyme in Q4 2020 and held it in 6 quarters.
  • Bridgefront Capital's Halozyme position peaked at $513K in Q4 2020.
  • 617 funds tracked by Wall St. Rank held Halozyme as of Q4 2025.

Based on Bridgefront Capital's 13F filing for Q4 2025, filed 13 Feb 2026.